> ⚠️ **Illustrative — fictional company, figures, and findings. "Acme RevOps, Inc." is a fictional placeholder; nothing here is about any real company.**

# Acquisition Review — Acme RevOps, Inc. (a fictional company)

**From:** Corp Dev, Meridian Growth Partners
**To:** Investment Committee
**Re:** Project Loom — proposed acquisition of Acme RevOps, Inc.

## The question

Acme RevOps has put itself up for sale through a banker-run process. We have an
exclusivity window and a data room. The IC needs a decision:

> **Go / no-go — and if go, at what price?** The seller is asking **$336M**.

We are the strategic acquirer: Acme RevOps's RevOps-automation platform plugs a hole in
our own product suite, and our enterprise sales motion could carry Acme RevOps upmarket.
This is a control acquisition (100% of equity), cash-and-stock, intended to be a
platform extension, not a financial-only play.

## The target (from the teaser + data room index)

- **Acme RevOps, Inc.** — B2B SaaS, RevOps / workflow-automation for mid-market GTM teams.
- Founded 2017, ~210 FTEs, HQ Austin TX, ~31% of revenue from EU customers.
- **ARR $42.0M**, growing **38% YoY** (was 47% two years ago — decelerating).
- **NRR 109%**, **GRR 88%**, gross margin **74%**, net-revenue burn multiple **1.8x**.
- **Asking price $336M = 8.0× ARR.** Last private round (Series C, 2023) was at $390M post.
- Top-3 customers = **22% of ARR**; largest single customer **9%** and up for renewal in 7 months.
- Shipped an **AI "auto-sequencing" feature** 5 months ago; ~40% of new logos cite it.

## Known hairs (surfaced in the teaser — diligence must confirm)

- A **SOC 2 Type II** report exists but the **access-review control skipped a quarter**
  during the last observation period; the report carries one exception.
- EU customer data flows to **two subprocessors with no DPA** on file.
- The new AI feature processes EU personal data (training + inference).

## What the IC wants

1. A recommendation: **GO / GO-WITH-CONDITIONS / NO-GO**, with the price we should offer.
2. The strongest case *for* and the strongest case *against* — not a blended mush.
3. Five independent C-suite reads (CFO, CEO, CTO, CRO, GC), run so that no one lens
   anchors the others.
4. A compliance verdict that is allowed to **veto** a financially attractive deal.

## Constraints

- Decision needed before the exclusivity window closes.
- Our hurdle rate for platform M&A is **20% IRR**; we will not fund a negative-NPV deal
  without naming the strategic reason.
- Maximum check the fund will write for a single platform deal this cycle: **$300M**.
